• 1
    Nilsson UR, Muller-Eberhard HJ. Isolation of b1F-globulin from human serum, and its characterisation as the fifth component of complement. J Exp Med 1965; 122:27790.
  • 2
    Schwaeble W, Schwaiger H, Brooimans RA et al. Human complement factor H. Tissue specificity in the expression of three different mRNA species. Eur J Biochem 1991; 198:399404.
  • 3
    Van Den Dobbelsteen ME, Verhasselt V, Kaashoek JG et al. Regulation of C3 and factor H synthesis of human glomerular mesangial cells by IL-1 and interferon-gamma. Clin Exp Immunol 1994; 95:17380.
  • 4
    Alexander JJ, Quigg RJ. The simple design of complement factor H: looks can be deceiving. Mol Immunol 2007; 44:12332.
  • 5
    Harrison RA, Lachmann PJ. The physiological breakdown of the third component of human complement. Mol Immunol 1980; 17:920.
  • 6
    Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 1977; 146:25770.
  • 7
    Conrad DH, Carlo JR, Ruddy S. Interaction of beta1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding. J Exp Med 1978; 147:1792805.
  • 8
    Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA 1976; 73:326872.
  • 9
    Pangburn MK, Muller-Eberhard HJ. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci USA 1978; 75:241620.
  • 10
    Nagaki K, Iida K, Okubo M, Inai S. Reaction mechanisms of beta1H globulin. Int Arch Allergy Appl Immunol 1978; 57:22132.
  • 11
    Pangburn MK, Morrison DC, Schreiber RD, Muller-Eberhard HJ. Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol 1980; 124:97782.
  • 12
    Fearon DT. Regulation by membrane sialic acid of beta1H-dependent decay − dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 1978; 75:19715.
  • 13
    Kazatchkine MD, Fearon DT, Austen KF. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 1979; 122:7581.
  • 14
    Kuhn S, Zipfel PF. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur J Immunol 1996; 26:23837.
  • 15
    Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM. Identification of complement regulatory domains in human factor H. J Immunol 1995; 155:34856.
  • 16
    Sharma AK, Pangburn MK. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci USA 1996; 93:109961001.
  • 17
    Pangburn MK. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 2000; 49:14957.
  • 18
    Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:4214.
  • 19
    Haines JL, Hauser MA, Schmidt S et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:41921.
  • 20
    Hageman GS, Anderson DH, Johnson LV et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102:722732.
  • 21
    Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:3859.
  • 22
    Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41:35567.
  • 23
    Levy M, Halbwachs-Mecarelli L, Gubler MC et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30:94956.
  • 24
    Licht C, Heinen S, Jozsi M et al. Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006; 70:4250.
  • 25
    Lopez-Larrea C, Dieguez MA, Enguix A, Dominguez O, Marin B, Gomez E. A familial deficiency of complement factor H. Biochem Soc Trans 1987; 15:6489.
  • 26
    Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15:78795.
  • 27
    Vaziri-Sani F, Holmberg L, Sjoholm AG et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 2006; 69:9818.
  • 28
    Rodriguez de Cordoba S, Goicoechea de Jorge E. Translational mini-review series on complement factor H: genetics and disease associations of the human complement factor H. Clin Exp Immunol 2008; 151:113.
  • 29
    Bircan Z, Toprak D, Kilicaslan I et al. Factor H deficiency and fibrillary glomerulopathy. Nephrol Dial Transplant 2004; 19:72730.
  • 30
    Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007; 22:87480.
  • 31
    Rougier N, Kazatchkine MD, Rougier JP et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9:231826.
  • 32
    Ohali M, Shalev H, Schlesinger M et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 1998; 12:61924.
  • 33
    Fijen CA, Kuijper EJ, Te Bulte M et al. Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol 1996; 105:51116.
  • 34
    Vogt BA, Wyatt RJ, Burke BA, Simonton SC, Kashtan CE. Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 1995; 9:1115.
  • 35
    Pichette V, Querin S, Schurch W, Brun G, Lehner-Netsch G, Delage JM. Familial hemolytic–uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994; 24:93641.
  • 36
    Nielsen HE, Christensen KC, Koch C, Thomsen BS, Heegaard NH, Tranum-Jensen J. Hereditary, complete deficiency of complement factor H associated with recurrent meningococcal disease. Scand J Immunol 1989; 30:71118.
  • 37
    Brai M, Misiano G, Maringhini S, Cutaja I, Hauptmann G. Combined homozygous factor H and heterozygous C2 deficiency in an Italian family. J Clin Immunol 1988; 8:506.
  • 38
    Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981; 46:11019.
  • 39
    Sanchez-Corral P, Bellavia D, Amico L, Brai M, Rodriguez de Cordoba S. Molecular basis for factor H and FHL-1 deficiency in an Italian family. Immunogenetics 2000; 51:3669.
  • 40
    Schmidt BZ, Fowler NL, Hidvegi T, Perlmutter DH, Colten HR. Disruption of disulfide bonds is responsible for impaired secretion in human complement factor H deficiency. J Biol Chem 1999; 274:117828.
  • 41
    Ault BH, Schmidt BZ, Fowler NL et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997; 272:2516875.
  • 42
    Caprioli J, Bettinaglio P, Zipfel PF et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12:297307.
  • 43
    Buddles MR, Donne RL, Richards A, Goodship J, Goodship TH. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 2000; 66:17212.
  • 44
    Ying L, Katz Y, Schlesinger M et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 1999; 65:153846.
  • 45
    Naked GM, Florido MP, Ferreira de Paula P, Vinet AM, Inostroza JS, Isaac L. Deficiency of human complement factor I associated with lowered factor H. Clin Immunol 2000; 96:1627.
  • 46
    Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int 1995; 47:64356.
  • 47
    Berger J, Galle P. Alteration singuliere des membranes basales du rein.J Urol Nephrol 1962; 68:11622.
  • 48
    Droz D, Zanetti M, Noel LH, Leibowitch J. Dense deposits disease. Nephron 1977; 19:111.
  • 49
    Habib R, Gubler MC, Loirat C, Maiz HB, Levy M. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int 1975; 7:20415.
  • 50
    Sibley RK, Kim Y. Dense intramembranous deposit disease: new pathologic features. Kidney Int 1984; 25:66070.
  • 51
    Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20:60516.
  • 52
    Smith RJ, Alexander J, Barlow PN et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:244756.
  • 53
    Strife CF, McEnery PT, McAdams AJ, West CD. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7:6572.
  • 54
    Kim Y, Vernier RL, Fish AJ, Michael AF. Immunofluorescence studies of dense deposit disease. The presence of railroad tracks and mesangial rings. Lab Invest 1979; 40:47480.
  • 55
    Falk RJ, Sisson SP, Dalmasso AP, Kim Y, Michael AF, Vernier RL. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 1987; 9:1218.
  • 56
    Spitzer RE, Vallota EH, Forristal J et al. Serum C′3 lytic system in patients with glomerulonephritis. Science 1969; 164:4367.
  • 57
    Daha MR, Fearon DT, Austen KF. C3 Nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 1976; 116:17.
  • 58
    Cameron JS, Turner DR, Heaton J et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74:17592.
  • 59
    Schena FP, Pertosa G, Stanziale P, Vox E, Pecoraro C, Andreucci VE. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis. Clin Nephrol 1982; 18:2406.
  • 60
    Sissons JG, West RJ, Fallows J et al. The complement abnormalities of lipodystrophy. N Engl J Med 1976; 294:4615.
  • 61
    Gewurz AT, Imherr SM, Strauss S, Gewurz H, Mold C. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol 1983; 54:2538.
  • 62
    Vargas R, Thomson KJ, Wilson D et al. Mesangiocapillary glomerulonephritis with dense ‘deposits’ in the basement membranes of the kidney. Clin Nephrol 1976; 5:7382.
  • 63
    Leibowitch J, Halbwachs L, Wattel S, Gaillard MH, Droz D. Recurrence of dense deposits in transplanted kidney: II. Serum complement and nephritic factor profiles. Kidney Int 1979; 15:396403.
  • 64
    Braun MC, Stablein DM, Hamiwka LA, Bell L, Bartosh SM, Strife CF. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16:222533.
  • 65
    Droz D, Nabarra B, Noel LH, Leibowitch J, Crosnier J. Recurrence of dense deposits in transplanted kidneys: I. Sequential survey of the lesions. Kidney Int 1979; 15:38695.
  • 66
    Galle P, Hinglais N, Crosnier J. Recurrence of an original glomerular lesion in three renal allografts. Transplant Proc 1971; 3:36870.
  • 67
    Andresdottir MB, Assmann KJ, Hoitsma AJ, Koene RA, Wetzels JF. Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome. Nephrol Dial Transplant 1999; 14:172331.
  • 68
    Meri S, Koistinen V, Miettinen A, Tornroth T, Seppala IJ. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 1992; 175:93950.
  • 69
    Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999; 163:45906.
  • 70
    Linshaw MA, Stapleton FB, Cuppage FE et al. Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. Am J Nephrol 1987; 7:4707.
  • 71
    Marder HK, Coleman TH, Forristal J, Beischel L, West CD. An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis. Kidney Int 1983; 23:74958.
  • 72
    Servais A, Fremeaux-Bacchi V, Lequintrec M et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:1939.
  • 73
    Simpson IJ, Moran J, Evans DJ, Peters DK. Prolonged complement activation in mice. Kidney Int 1978; 13:46771.
  • 74
    Verroust PJ, Wilson CB, Dixon FJ. Lack of nephritogenicity of systemic activation of the alternate complement pathway. Kidney Int 1974; 6:15769.
  • 75
    Jansen JH, Hogasen K, Mollnes TE. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 1993; 143:135665.
  • 76
    Jansen JH, Hogasen K, Harboe M, Hovig T. In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int 1998; 53:33149.
  • 77
    Hogasen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95:105461.
  • 78
    Jansen JH, Hogasen K, Grondahl AM. Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H. Vet Rec 1995; 137:2404.
  • 79
    Hegasy GA, Manuelian T, Hogasen K, Jansen JH, Zipfel PF. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002; 161:202734.
  • 80
    Hogasen K, Jansen JH, Harboe M. Eradication of porcine factor H deficiency in Norway. Vet Rec 1997; 140:3925.
  • 81
    Pickering MC, Cook HT, Warren J et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31:4248.
  • 82
    Pickering MC, Warren J, Rose KL et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 2006; 103:964954.
  • 83
    Rose KL, Paixao-Cavalcante D, Fish J et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. Mol Immunol 2007; 44:3924.
  • 84
    Vyse TJ, Spath PJ, Davies KA et al. Hereditary complement factor I deficiency. Q J Med 1994; 87:385401.
  • 85
    Amadei N, Baracho GV, Nudelman V, Bastos W, Florido MP, Isaac L. Inherited complete factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H. Scand J Immunol 2001; 53:61521.
  • 86
    Genel F, Sjoholm AG, Skattum L, Truedsson L. Complement factor I deficiency associated with recurrent infections, vasculitis and immune complex glomerulonephritis. Scand J Infect Dis 2005; 37:61518.
  • 87
    Sadallah S, Gudat F, Laissue JA, Spath PJ, Schifferli JA. Glomerulonephritis in a patient with complement factor I deficiency. Am J Kidney Dis 1999; 33:11537.
  • 88
    Sacks SH, Zhou W, Pani A, Campbell RD, Martin J. Complement C3 gene expression and regulation in human glomerular epithelial cells. Immunology 1993; 79:34854.
  • 89
    Sacks S, Zhou W, Campbell RD, Martin J. C3 and C4 gene expression and interferon-gamma-mediated regulation in human glomerular mesangial cells. Clin Exp Immunol 1993; 93:41117.
  • 90
    West CD, Witte DP, McAdams AJ. Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 2001; 37:112030.
  • 91
    Neumann HP, Salzmann M, Bohnert-Iwan B et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003; 40:67681.
  • 92
    Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53:83644.
  • 93
    Richards A, Buddles MR, Donne RL et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18–20, a domain important for host cell recognition. Am J Hum Genet 2001; 68:48590.
  • 94
    Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001; 68:47884.
  • 95
    Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41:848.
  • 96
    Noris M, Brioschi S, Caprioli J et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362:15427.
  • 97
    Richards A, Kemp EJ, Liszewski MK et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003; 100:1296671.
  • 98
    Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007; 104:2405.
  • 99
    Manuelian T, Hellwage J, Meri S et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111:118190.
  • 100
    Sanchez-Corral P, Perez-Caballero D, Huarte O et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002; 71:128595.
  • 101
    Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004; 41:814.
  • 102
    Pickering MC, De Jorge EG, Martinez-Barricarte R et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204:124956.
  • 103
    Cheng ZZ, Hellwage J, Seeberger H, Zipfel PF, Meri S, Jokiranta TS. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Mol Immunol 2006; 43:9729.
  • 104
    Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108:126779.
  • 105
    Donne RL, Abbs I, Barany P et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002; 40:E22.
  • 106
    Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14:70312.
  • 107
    Esparza-Gordillo J, Jorge EG, Garrido CA et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006; 43:176975.
  • 108
    Zipfel PF, Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 43: e41.
  • 109
    Jozsi M, Strobel S, Zipfel SLH et al. Factor H autoantibodies in atypical hemolytic uraemic syndrome correlate with CFHR1/CFHR3 deficiency and affect recognition functions. Mol Immunol 2007; 44:3924.
  • 110
    Jozsi M, Strobel S, Dahse HM et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110:151618.